Is 7.5 mg of Mirtazapine Enough for Depression?

A dose of 7.5 mg of mirtazapine falls below the established therapeutic range for treating depression on its own. Most clinical guidelines set 15 mg as the minimum effective starting dose, with optimal antidepressant effects seen around 30 mg. That said, 7.5 mg is not a meaningless dose, and prescribers use it deliberately in specific situations, from easing anxiety-prone patients onto the medication to boosting an existing antidepressant regimen. The story behind why such a low dose exists and what it can and cannot do is more nuanced than a simple “not enough.”

Where 7.5 mg Sits in the Dosing Range

The recommended starting dose for mirtazapine in depression is 15 mg once daily, typically taken at bedtime. From there, the dose is often increased to 30 mg after a couple of weeks if the response is inadequate, and some patients go up to 45 mg.

¹ The licensed dosage range spans 15 to 45 mg in most countries, though early pharmacokinetic work characterized the drug’s behavior across a wider range of 15 to 80 mg daily.²

At 7.5 mg, you are at half the minimum licensed antidepressant dose. No major guideline recommends 7.5 mg as a standalone treatment for major depression. When prescribers do use it, they typically frame it as a temporary starting step for people who are especially sensitive to medication side effects, or as an add-on to another antidepressant rather than a stand-alone treatment.

The Sedation Paradox at Low Doses

One of mirtazapine’s best-known quirks is that lower doses tend to be more sedating than higher ones. This sounds counterintuitive, but it comes down to the drug’s receptor profile. At low concentrations, mirtazapine blocks histamine receptors strongly, which causes drowsiness. As the dose climbs, the drug begins activating noradrenergic pathways that counteract that sedation. The result is that someone on 7.5 mg or 15 mg often feels sleepier than someone on 30 mg or 45 mg.³

A brain-imaging study using PET scans in healthy volunteers confirmed just how powerful this histamine blockade is: mirtazapine occupied 80 to 90 percent of histamine receptors in the brain’s outer cortex, and the degree of occupancy tracked closely with how sleepy participants felt.⁴ This is why 7.5 mg can knock you out at night without doing much for your mood during the day. At that dose, you are essentially getting the sedating and appetite-stimulating side of the drug without unlocking the full antidepressant machinery.

Early safety reviews flagged this explicitly, noting that increased sedation appeared linked to subtherapeutic doses, and that it was reported far less often once patients reached at least 15 mg taken as a single evening dose from the start of treatment.² In other words, 7.5 mg is firmly in the zone where sedation dominates.

When Prescribers Intentionally Use 7.5 mg

Despite falling below the therapeutic floor for depression, 7.5 mg has carved out a niche in clinical practice. Dosing guides describe it as a starting point for two groups: anxiety-prone patients, where starting at the standard 15 mg might provoke an initial worsening of anxiety symptoms, and elderly patients or those with significant kidney impairment, where drug clearance is slower and accumulation is a concern.⁵ In these cases, 7.5 mg is a stepping stone. The intention is almost always to increase the dose within a week or two once the person adjusts.

The distinction matters. Starting at 7.5 mg for a few days to let your body acclimate is a reasonable prescribing strategy. Staying on 7.5 mg indefinitely as your only antidepressant is not supported by the clinical evidence for depression treatment. If your prescriber keeps you at 7.5 mg long-term, it is worth asking whether the goal is actually depression treatment or something else, like sleep support.

What the Dose-Response Curve Actually Shows

A large meta-analysis published in The Lancet Psychiatry examined fixed-dose trials of several antidepressants, including mirtazapine, to map out how efficacy changes at different doses. The finding was clear: for mirtazapine, antidepressant efficacy rose steadily up to about 30 mg and then actually declined at higher doses.⁶ At the same time, side effects climbed steeply with dose, meaning the best balance of benefit and tolerability landed in the lower end of the licensed range, around 15 to 30 mg.⁷

Notice that 7.5 mg does not appear anywhere in this sweet spot. The curve tells us that you need to reach at least the lower licensed range to see meaningful antidepressant effects, and that going much beyond 30 mg does not buy you additional mood improvement. So the evidence converges on a fairly narrow window for mirtazapine’s antidepressant action, and 7.5 mg is outside it.

Blood Levels and the Threshold for Response

There is also a pharmacokinetic argument for why 7.5 mg is unlikely to treat depression effectively as monotherapy. A study examining the relationship between mirtazapine plasma concentrations and clinical outcomes found that patients who responded to treatment had higher blood levels of the drug, with a threshold concentration of about 30 ng/mL separating responders from non-responders.⁸ At half the standard starting dose, most people will not reliably reach that plasma level. How quickly you metabolize the drug matters, too: genetic variations in the liver enzyme CYP2D6 can change mirtazapine clearance dramatically. Ultrarapid metabolizers clear the drug roughly two and a half times faster than poor metabolizers, which means the same 7.5 mg dose can produce very different blood levels in two different people.⁹

If you happen to be a fast metabolizer, 7.5 mg is even less likely to produce meaningful antidepressant blood levels. Conversely, a very slow metabolizer on 7.5 mg might accumulate enough drug to approach the therapeutic range, but this is an unpredictable gamble, not a strategy.

The Add-On Strategy Where 7.5 mg Does Show Up

There is one scenario in the research where 7.5 mg of mirtazapine shows a clear benefit for depression, and that is when it is added on top of an existing SSRI rather than used alone. A double-blind study randomly assigned patients with major depression to receive either escitalopram 10 mg plus 7.5 mg of mirtazapine or escitalopram 10 mg plus placebo. The combination group showed better efficacy and earlier remission, with more patients qualifying as responders.¹⁰

A separate study in Indian patients produced a similar result: adding 7.5 mg of mirtazapine to conventional-dose SSRIs led to faster improvement, more responders, and more patients reaching remission compared to SSRI treatment alone.¹¹ The logic here is that mirtazapine works through a different mechanism than SSRIs, so the two drugs complement each other. Even a subtherapeutic dose of mirtazapine, when stacked on top of a full-dose SSRI, can push the overall treatment effect into a more effective range.

This is an important distinction. If your prescriber has you on 7.5 mg of mirtazapine alongside another antidepressant, the combination may be delivering real antidepressant benefit. That is very different from 7.5 mg on its own.

Why 7.5 mg Gets Prescribed So Often Anyway

If 7.5 mg is subtherapeutic for depression, why do so many people end up on it? The answer is sleep. Mirtazapine’s potent histamine blockade at low doses makes it an effective sedative, and a considerable share of prescriptions for 7.5 mg are intended for insomnia rather than depression, even though the drug is not officially approved for that use in most countries.

A randomized, double-blind, placebo-controlled crossover trial tested 7.5 mg of mirtazapine for transient insomnia induced by noise stress. Compared to placebo, 7.5 mg increased total sleep time by about half an hour and reduced the number of nighttime awakenings by 35 to 40 percent. The drug particularly boosted deep sleep, the stage most associated with feeling rested.¹² A larger trial in older adults with chronic insomnia, the MIRAGE study, also found mirtazapine superior to placebo on multiple sleep outcomes including total sleep time and sleep efficiency.¹³

So if you are on 7.5 mg and your primary complaints are poor sleep alongside low mood, your prescriber may be using the drug primarily for the sleep piece, with any mild mood benefit as a bonus. The trouble is that the depression itself often needs its own targeted treatment at an adequate dose, whether that means increasing the mirtazapine or adding another medication.

Appetite and Weight at Low Doses

Another reason 7.5 mg gets prescribed is its appetite-stimulating effect, which can be useful in older adults or medically ill patients who are underweight or losing weight. The same histamine blockade that causes sedation also drives increased appetite and, over time, weight gain. Research has confirmed that mirtazapine increases appetite and weight compared to placebo and other antidepressants.¹⁴

For someone who is underweight and depressed, this side effect is actually a feature. But for anyone at a healthy weight or already overweight, the appetite stimulation at 7.5 mg is an all-downside proposition: you get the metabolic effects without the antidepressant benefit. A preprint analyzing off-label low-dose mirtazapine use in Swedish adolescents flagged metabolic concerns even at low doses, including a substantially higher rate of prediabetes in that population.¹⁵ That preprint has not yet been peer-reviewed, so the specific numbers should be treated cautiously, but the general concern about metabolic risk at low doses aligns with what is known about the drug’s pharmacology.

How to Think About Your Dose

If you have been prescribed 7.5 mg of mirtazapine and you are wondering whether it is enough for your depression, the honest answer depends on the context:

As monotherapy for depression: The evidence says no. You are below the therapeutic floor. The dose-response data, the plasma-level studies, and every major clinical guideline point to 15 mg as the minimum starting dose for depression, with the best results around 30 mg.
As a starting dose before titrating up: Reasonable and common, especially if you are prone to anxiety or medication sensitivity. But the plan should include a dose increase within one to two weeks.
As an add-on to an SSRI or other antidepressant: There is genuine evidence supporting this. The combination can produce better and faster antidepressant effects than the SSRI alone, even with mirtazapine at just 7.5 mg.
For insomnia or appetite: This is where 7.5 mg has its clearest evidence base, particularly for sleep. If depression is your primary concern, though, a sleep aid is not treating the core problem.

The worst-case scenario is staying on 7.5 mg indefinitely as your sole antidepressant without a clear conversation about why. You end up managing side effects, mainly sedation and weight gain, without getting the full antidepressant effect the drug is capable of. If that sounds familiar, it is a good reason to bring the dose question back to your prescriber.

Genetics and Individual Variation

One layer of complexity that rarely comes up in these conversations is that drug metabolism varies enormously between individuals. As mentioned earlier, variations in CYP2D6 can change mirtazapine’s clearance by a factor of two or more.⁹ CYP2D6 accounted for about a quarter of the drug’s total clearance in people with typical metabolism, but that share jumped to over half in ultrarapid metabolizers. The practical upshot: two patients on the same dose can have vastly different amounts of active drug circulating in their blood.

Pharmacogenomic testing, which identifies your metabolizer status through a simple cheek swab, is becoming more accessible. If you have tried mirtazapine and felt nothing at doses that should be working, or if you experienced strong side effects at a low dose, your metabolism may be part of the explanation. It does not change the general recommendation that 7.5 mg is subtherapeutic for depression, but it adds nuance to why a given person might feel over-medicated or under-medicated at any particular dose. The threshold plasma concentration of about 30 ng/mL that separates responders from non-responders is a useful benchmark, and reaching it predictably requires at least 15 mg in most people.⁸

Compliance and Side Effects at Different Doses

One argument sometimes made in favor of low-dose prescribing is that patients tolerate it better and are more likely to keep taking the medication. There is some truth to this at the population level: the Lancet Psychiatry meta-analysis found that mirtazapine’s best acceptability, meaning the dose where fewest people dropped out for any reason, landed in the lower part of the licensed range.⁷ Dropout rates due to side effects climbed steeply as doses increased. So there is a real tension between efficacy, which favors 30 mg, and tolerability, which favors the lower end.

But that lower end is 15 mg, not 7.5 mg. The trials in the meta-analysis used licensed doses, which start at 15 mg. Going below 15 mg might improve tolerability further for some individuals, but it also removes you from the dose range where antidepressant efficacy has been demonstrated in controlled trials. You can tolerate a medication perfectly while getting no antidepressant benefit from it, which is arguably the worst of both worlds. A real-world retrospective study comparing mirtazapine to duloxetine for fibromyalgia found that all patients on mirtazapine reported adverse effects and compliance was notably poor, suggesting that even with the drug’s sedating and appetite-stimulating properties working in your favor, tolerability can still be an issue.¹⁶

The bottom line on compliance is pragmatic: if 7.5 mg is what allows you to stay on the medication at all while gradually increasing, that temporary tradeoff serves the treatment plan. If 7.5 mg is where you stay because a higher dose feels impossible, it is worth exploring why, whether that is side effects, anxiety about dose changes, or something else entirely, rather than settling for a dose that is unlikely to treat the depression itself.